BridgeBio Pharma
BBIO
433 hedge funds and large institutions have $14.4B invested in BridgeBio Pharma in 2025 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 154 increasing their positions, 139 reducing their positions, and 51 closing their positions.
451% more call options, than puts
Call options by funds: $894M | Put options by funds: $162M
98% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 51
57% more funds holding in top 10
Funds holding in top 10: 14 → 22 (+8)
50% more capital invested
Capital invested by funds: $9.62B → $14.4B (+$4.79B)
11% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 139
10% more funds holding
Funds holding: 392 → 433 (+41)
2.3% more ownership
Funds ownership: 96.85% → 99.15% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Brooklands Fund Management
London,
United Kingdom
|
+$181M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$148M |
| 3 |
Janus Henderson Group
London,
|
+$148M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.3M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$64.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$104M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$100M |
| 3 |
ACM
Aisling Capital Management
New York
|
-$65.6M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$54.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$51.2M |
BBIO Hedge Fund Activity: Q4 2025 in Review
433 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2025, worth a combined $14.4B — up 50% from $9.62B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new BBIO positions and 51 closed out — a net gain of 50 holders — while 154 added to existing stakes and 139 trimmed.
The largest buyer was Brooklands Fund Management, opening a new position worth an estimated $181M. The largest seller was Viking Global Investors, cutting an estimated $104M.
- 433 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2025, up from 392 in Q3 2025.
- Funds reported $14.4B of BridgeBio Pharma stock for Q4 2025, up 50% quarter-over-quarter.
- 101 funds opened new BridgeBio Pharma positions in Q4 2025 and 51 closed out, a net change of +50 holders.
- The largest BridgeBio Pharma buyer in Q4 2025 was Brooklands Fund Management, an estimated $181M added.
- The largest BridgeBio Pharma seller in Q4 2025 was Viking Global Investors, an estimated $104M sold.
Based on aggregated 13F filings for Q4 2025.